News

Video

What Are the Concerns of Patients with Aspirin-Exacerbated Respiratory Disease?

Author(s):

Key Takeaways

  • AERD affects 7% of adults with asthma and 14% with severe asthma, causing chronic inflammation in lungs and sinuses.
  • COX-1 inhibitors, such as aspirin, can trigger severe, potentially fatal AERD attacks within 20 minutes.
SHOW MORE

In this segment of the latest Lungcast episode, the characteristics of AERD and the concerns of patients were highlighted.

The disorder known as Aspirin-Exacerbated Respiratory Disease (AERD) or Samter’s triad is a chronic inflammatory condition impacting patients’ lungs and sinuses. Affecting close to 7% of adults who have asthma and 14% who have severe asthma, AERD is a collection of conditions which typically begins with nasal symptoms or with rhinitis, often before developing into severe asthma which may require surgery.

During the most recent episode of Lungcast, host Albert Rizzo, MD, chief medical officer of the American Lung Association (ALA), spoke with 3 guests regarding AERD and its impacts on patients. This monthly respiratory health podcast series is produced by HCPLive and by the ALA.

In the above segment, Rizzo spoke with allergist and immunologist Mitchell Grayson, MD, of Nationwide Children’s Hospital. Rizzo also spoke with patient advocate Rhonda Nelson and her husband Wayne Nelson, a musician known for his work as the lead singer of The Little River Band.

This segment of the latest episode highlighted the major concerns of those suffering from Samter’s triad, with Grayson noting that individuals with AERD who take Cyclooxygenase-1 (COX-1) inhibitors such as aspirin can have symptoms within 20 minutes. They may suffer from a severe AERD attack that can even be fatal in certain circumstances.

After Grayson's discussion of symptoms and characteristics, Rhonda and Wayne Nelson spoke of their experiences dealing with AERD. Rhonda Nelson has lived with the disorder for 22 years and her husband has helped her throughout the process.

Lungcast is a monthly respiratory news podcast series hosted by Albert Rizzo, MD, chief medical officer of the ALA, and produced by HCPLive.

Subscribe to Lungcast on Spotify here, or listen to the episode below.

Related Videos
Jörn Schattenberg, MD | Credit: Novo Nordisk
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Jörn Schattenberg, MD | Credit: Novo Nordisk
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
© 2024 MJH Life Sciences

All rights reserved.